Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.

Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma.

Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.

Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.

Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations.
Patel AB, Pettijohn EM, Abedin SM, Raps E, Deininger MW.